The 39 most recent market catalysts affecting $JNJ, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 25, 2026
Corporate Catalyst
Bullish
Impact 65
Johnson & Johnson Announces That TREMFYA Met Primary And Major Secondary Endpoints Demonstrating Both Improvement In Axial Symptoms And Reduction In Inflammation By MRI Assessment In The Phase 4 STAR Study Evaluating Biologic-Naïve Adults With Active Psoriatic Arthritis And Axial Involvement
Johnson & Johnson's TREMFYA, an IL-23 inhibitor, successfully met its primary and major secondary endpoints in the Phase 4 STAR study for axial psoriatic arthritis. This is signifi…
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 75
Johnson & Johnson Announces Data From Phase 3 MajesTEC-3 Trial Demonstrates Disease Control, Survival With TECVAYLI Plus DARZALEX FASPRO To Treat Relapsed Or Refractory Multiple Myeloma
Johnson & Johnson announced new data from its Phase 3 MajesTEC-3 study, showing that the combination of TECVAYLI and DARZALEX FASPRO achieved sustained disease control and survival…
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 65
Johnson & Johnson Drug Shows Improved Mania Symptoms in Bipolar Patients
Johnson & Johnson reported positive topline results from a Phase 3 study for Caplyta (lumateperone), showing significant and rapid improvement in manic symptoms for adults with bip…
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 75
Johnson & Johnson Announces CAPLYTA Demonstrates Reduction In Signs, Symptoms Of Acute Manic Episodes Associated With Bipolar I Disorder In Phase 3 Trial
Johnson & Johnson announced positive topline results from a pivotal Phase 3 study for CAPLYTA (lumateperone) in treating manic episodes associated with bipolar I disorder. This is …
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 75
Johnson & Johnson Says Lung Cancer Drug Shows Reduced Side Effects and Longer Patient Survival
Johnson & Johnson released new clinical data for its lung cancer drug, RYBREVANT FASPRO, from two studies. The COPERNICUS study showed a better safety profile with fewer discontinu…
Sep 15, 2026
Corporate Catalyst
Bearish
Impact 65
Reported Earlier, J&J's Subcutaneous RYBREVANT FASPRO Plus LAZCLUZE Shows Lower Rash, Administration-Related Reaction, Venous Thromboembolism Rates Than Intravenous MARIPOSA Regimen
Johnson & Johnson (JNJ) released new clinical data for its subcutaneous RYBREVANT FASPRO plus LAZCLUZE combination, showing significantly lower rates of adverse events like rash, b…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 75
Johnson & Johnson’s RYBREVANT Combination Extends Survival To 34.3 Months In EGFR Exon 20+ Lung Cancer
Johnson & Johnson announced compelling new data for its drug RYBREVANT (amivantamab-vmjw) when combined with chemotherapy, showing a median overall survival of 34.3 months in patie…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 75
Reported Earlier, Johnson & Johnson Says Rybrevant Plus Chemotherapy Cuts Risk Of Death By 43% Versus Chemotherapy Alone When Adjusted For Crossover In Final PAPILLON Overall Survival Analysis
Johnson & Johnson reported final overall survival analysis data for its drug Rybrevant, showing a 43% reduction in the risk of death when combined with chemotherapy for a specific …
Sep 10, 2026
Market Technicals
Bullish
Impact 55
HSBC Maintains Buy on Johnson & Johnson, Raises Price Target to $320
HSBC analyst Rajesh Kumar maintained a 'Buy' rating on Johnson & Johnson and raised the price target from $290 to $320. This action signals increased confidence from the analyst in…
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 55
Johnson & Johnson Receives CE Marking For ACUVUE OASYS MAX 2-Week, New Reusable Contact Lens Featuring Proprietary MAX Technologies To Deliver Lasting Comfort And Clear Vision, Even At Day 14
Johnson & Johnson has secured CE Marking for its ACUVUE OASYS MAX 2-Week contact lens, a crucial regulatory approval for the European market. This allows J&J to introduce a new, ad…
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 65
Reported September 8, 2026: 'Tylenol Use In Pregnancy May Be Linked With Uterus, Ovary Changes In Daughters' - Reuters News
Reuters reported on new research suggesting a link between Tylenol (acetaminophen) use during pregnancy and reproductive changes in female offspring. This matters because Johnson &…
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 55
UBS Maintains Buy on Johnson & Johnson, Raises Price Target to $320
UBS analyst Michael Yee has maintained a 'Buy' rating on Johnson & Johnson and raised the price target from $280 to $320. This analyst action signals continued confidence in JNJ's …
Aug 28, 2026
Corporate Catalyst
Neutral
Impact 65
FDA Approves Stelara for Pediatric Ulcerative Colitis
The FDA has approved Stelara, a drug developed by Johnson & Johnson, for a new indication: pediatric ulcerative colitis. This is a positive development for JNJ as it expands the ad…
Aug 26, 2026
Macro/Central Bank
Neutral
Impact 75
'White House to Announce New Drug Pricing Deals With Biotechs' - Bloomberg
The Bloomberg article reports that the White House is set to announce new drug pricing deals with biotech companies. This development is significant because it signals increased go…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 75
Johnson & Johnson Secures FDA Approval For First Rare Anemia Treatment
Johnson & Johnson's FDA approval for IMAAVY to treat warm autoimmune hemolytic anemia (wAIHA) is a significant positive development. This drug is the first specific therapy for thi…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 65
Johnson & Johnson Expands Robotic Bronchoscopy Push With AI, 3D Navigation Upgrade
Johnson & Johnson (JNJ) announced the U.S. 510(k) regulatory clearance for MONARCH QUEST 3, a significant software upgrade for its robotically-assisted bronchoscopy platform. This …
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Johnson & Johnson, Raises Price Target to $287
Guggenheim analyst Vamil Divan has maintained a 'Buy' rating on Johnson & Johnson and raised the price target from $270 to $287. This analyst upgrade signals a positive re-evaluati…
Aug 3, 2026
Market Technicals
Bullish
Impact 55
Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to $282
Wells Fargo's analyst Larry Biegelsen maintaining an 'Overweight' rating and raising the price target for Johnson & Johnson to $282 from $272 signals continued confidence in the co…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 75
Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline
Johnson & Johnson is making a strategic move to bolster its oncology pipeline by acquiring Firefly Bio and partnering with Sail Biomedicines. This is significant as it addresses a …
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 85
Johnson & Johnson Advances Cancer and Immunology Treatments With Major Biotech Deals
Johnson & Johnson has announced two major biotechnology deals: a $1 billion acquisition of Firefly Bio and a strategic partnership with Sail Biomedicines, including an option to pu…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
Johnson & Johnson Says FDA Grants Priority Review To Subcutaneous Amivantamab For Recurrent Or Metastatic Head And Neck Cancer, Citing 42% Overall Response Rate In OrigAMI-4 Study
The FDA's priority review for J&J's amivantamab is a significant positive catalyst for the company, indicating a faster path to potential market approval. The 42% overall response …
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 85
Johnson & Johnson Says 2026 Adj Operational EPS And Adj EPS Expected To Decrease By $0.64; 2027 Adj Operational EPS And Adj EPS Expected To Decrease By $1.36
Johnson & Johnson (JNJ) has disclosed a substantial reduction in its adjusted operational and reported EPS forecasts for 2026 and 2027. Specifically, the company expects a $0.64 de…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 85
Johnson & Johnson Reaches $5.5B Comprehensive Ovarian Talc Litigation Agreement Based On Participation Of At Least 95% Of Remaining Claims
Johnson & Johnson has reached a significant $5.5 billion agreement to settle ovarian talc litigation, a major legal challenge that has weighed on the company for years. This resolu…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 85
Reported Earlier, Johnson & Johnson Proposes $5.5B Resolution Of Roughly 76,000 Ovarian Talc Claims, With First Payment Of Up To $3B In 2027, Conditioned On 95% Plaintiff Participation
Johnson & Johnson (JNJ) has announced a proposed $5.5 billion resolution to settle roughly 76,000 ovarian talc claims. This is a significant development as it aims to remove a majo…
Jul 24, 2026
Corporate Catalyst
Neutral
Impact 55
FDA Approves First Nonprescription Fixed-Dose Combination Of Acetaminophen, Naproxen Sodium For 12-Hour Pain Relief
The FDA's approval of the first nonprescription fixed-dose combination of acetaminophen and naproxen sodium marks a new entry into the over-the-counter pain relief market. This mat…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 85
Johnson & Johnson Announces Topline Results From Phase 3 MonumenTAL-6 Study Evaluating TECVAYLI + TALVEY In Adult Patients With Multiple Myeloma; Study Demonstrated Statistically Significant And Clinically Meaningful Improvements In Progression-Free Survival And Overall Survival
Johnson & Johnson announced groundbreaking Phase 3 results for its TECVAYLI + TALVEY combination therapy in relapsed or refractory multiple myeloma. The study showed an 89% reducti…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 75
FDA Approves Johnson & Johnson Table-Integrated OTTAVA Robotic Surgery System
Johnson & Johnson (JNJ) has secured FDA De Novo authorization for its OTTAVA Robotic Surgical System, a significant milestone as it's the world's first table-integrated soft tissue…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 75
Johnson & Johnson Receives FDA De Novo Authorization For Its OTTAVA Robotic Surgical System
Johnson & Johnson announced FDA De Novo authorization for its OTTAVA Robotic Surgical System, allowing its commercial launch in the U.S. for various general surgery procedures. Thi…
Jul 22, 2026
Macro/Central Bank
Neutral
Impact 75
Trump Sets August 1 Start for Generic Drug Tariff Clock, Warns of 200% Duties: Companies Must 'Build Plant and Equipment' in US
Donald Trump announced a new policy to impose tariffs on imported generic drugs, starting with a two-year grace period followed by escalating duties of 100% and then 200%. This mov…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 55
Raymond James Maintains Outperform on Johnson & Johnson, Raises Price Target to $265
This filing discloses that Raymond James, a prominent financial services firm, has maintained its 'Outperform' rating on Johnson & Johnson and raised its price target. This action …
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to $272
Wells Fargo analyst Larry Biegelsen maintained an 'Overweight' rating on Johnson & Johnson and raised the price target from $263 to $272. This action signals continued confidence i…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Overweight on Johnson & Johnson, Raises Price Target to $294
Morgan Stanley analyst Terence Flynn has maintained an 'Overweight' rating on Johnson & Johnson (JNJ) and raised the price target from $284 to $294. This action signals a continued…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 65
Johnson & Johnson Unit DePuy Synthes Acquires Expanding Innovations, A Maker Of Expandable Implant Technology For Spinal Surgery; Financial Terms Not Disclosed
Johnson & Johnson's DePuy Synthes unit has acquired Expanding Innovations, a commercial-stage medical technology company focused on expandable implant technologies for spine surger…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 85
Johnson & Johnson Finds Growth Beyond Legacy Drugs, Lifts 2026 Outlook
Johnson & Johnson's Q2 2026 performance significantly surpassed analyst expectations, with both sales and adjusted earnings beating consensus estimates. This strong showing, partic…
Jul 15, 2026
Corporate Catalyst
Neutral
Impact 95
Johnson & Johnson Q2 Adj. EPS $2.90 Beats $2.85 Estimate, Sales $25.310B Beat $25.047B Estimate
Johnson & Johnson announced Q2 adjusted EPS of $2.90, surpassing the $2.85 estimate, and sales of $25.310 billion, beating the $25.047 billion estimate. This strong financial perfo…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 65
Johnson & Johnson Q2 Preview: Stock Near All-Time Highs, Market Expert Sees Rally to $282 – ‘Continue Their Winning Ways’
This filing is a pre-earnings report analysis for Johnson & Johnson (JNJ), detailing analyst consensus for Q2 revenue and EPS, and highlighting the company's consistent track recor…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 65
How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q2 Earnings
The filing primarily highlights analyst sentiment towards Johnson & Johnson (JNJ) with two analysts raising their price targets and maintaining positive ratings ahead of the Q2 ear…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 55
TD Cowen Maintains Buy on Johnson & Johnson, Raises Price Target to $300
TD Cowen's analyst Michael Nedelcovych has maintained a 'Buy' rating on Johnson & Johnson and raised the price target from $250 to $300. This action signals increased confidence in…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Johnson & Johnson, Raises Price Target to $287
RBC Capital analyst Shagun Singh maintained an 'Outperform' rating on Johnson & Johnson and raised the price target from $265 to $287. This action signals a strengthened positive o…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.